Financial Performance - Annovis reported cash and cash equivalents of $22.2 million as of March 31, 2025, up from $10.6 million a year earlier, representing a 109.4% increase[9] - The net loss for Q1 2025 was $5.5 million, compared to a net loss of $1.1 million in Q1 2024, indicating a significant increase in losses[9] - The basic and diluted net loss per share for Q1 2025 was $0.32, compared to $0.10 (basic) and $0.72 (diluted) in Q1 2024[13] - The total operating expenses for Q1 2025 were $6.3 million, down from $7.8 million in Q1 2024, reflecting a 19.5% reduction[13] Research and Development - Research and development expenses for Q1 2025 were $5.0 million, a decrease of 23.1% compared to $6.5 million in Q1 2024[9] - Annovis is conducting a pivotal Phase 3 clinical trial for early Alzheimer's disease, aiming to enroll approximately 760 participants[2] - Annovis participated in multiple key scientific conferences in early 2025, presenting findings from its Phase 3 PD trial and data on buntanetap[4] Intellectual Property - The company received a U.S. patent in January 2025 for methods related to the treatment and prevention of acute brain and nerve injuries using buntanetap[4] Administrative Expenses - General and administrative expenses remained stable at $1.3 million for both Q1 2025 and Q1 2024[9] - The company had 19.5 million shares of common stock outstanding as of March 31, 2025, an increase from 14.1 million shares a year prior[9]
Annovis Bio(ANVS) - 2025 Q1 - Quarterly Results